We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Azimut Hldg SPA | BIT:AZM | Italy | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.14 | -0.57% | 24.44 | 24.20 | 24.75 | 24.72 | 24.27 | 24.72 | 614,794 | 17:00:00 |
RNS Number:0774U Alizyme PLC 12 January 2004 FOR IMMEDIATE RELEASE 12 January 2004 ALIZYME FILES NEW PATENT APPLICATION FOR RENZAPRIDE Cambridge UK, 12 January 2004: Alizyme plc (LSE:AZM) announces that a Patent Application has been filed relating to renzapride, its compound in clinical development for the treatment of irritable bowel syndrome (IBS). This Patent Application relates to a crystal form of renzapride with improved pharmaceutical properties, its manufacture and use in medicine. If granted, it could provide exclusivity for this invention until 2024. Dr. Richard Palmer (Chief Executive Officer) commented: "The filing of this Patent Application, together with another Patent Application filed in September 2003 covering manufacture of renzapride, results from Alizyme's programme of work designed to extend the commercial exclusivity of renzapride beyond its current patent life. We look forward to seeing the outcome of this Application in commercially significant jurisdictions around the world over the next few years." For further information, please contact: Dr Richard Palmer, Chief Executive Officer Mr Tim McCarthy, Finance Director ALIZYME plc Tel No: + 44 (0)1223 896000 Lisa Baderoon BUCHANAN COMMUNICATIONS Tel No: + 44 (0)20 7466 5000 Further information on Alizyme can be found on the Company's website: www.alizyme.com Editors Note Alizyme plc Alizyme is a biopharmaceutical company, based in Cambridge, UK, targeting the treatment and management of gastrointestinal disorders, obesity and diabetes. It has a portfolio of products which in addition to renzapride (completed Phase IIb clinical programme for irritable bowel syndrome) includes COLAL-PREDTM? (Phase III approval for the maintenance of remission of ulcerative colitis), ATL-962 (completed Phase IIb trial for obesity) and ATL-104 (Phase IIa approval for mucositis). At the appropriate time Alizyme intends to license products to established pharmaceutical companies, which will complete development, gain marketing approval and commercialise the products. Irritable Bowel Syndrome IBS is a common gastrointestinal disorder. Important symptoms include abdominal pain, discomfort and bloating. In IBS, the normal contractile patterns of the gut are disrupted resulting in irregular or spasmodic bowel movements. Sufferers may experience either a constipation or a diarrhoea predominant form of IBS or, in 'mixed symptom' IBS, alternate between these conditions. It has been estimated that up to 20% of adults in developed countries are affected to some degree by IBS; of these between 20-30% consult a doctor. Current treatments, which are aimed at providing symptomatic relief to IBS sufferers, include laxatives, anti-diarrhoeal and antispasmodic products. These products, however, have limited efficacy for the condition and it is generally accepted that the market is poorly served. Renzapride Alizyme is currently investigating renzapride for the treatment of IBS. Renzapride is a potent full 5-HT4 receptor agonist; it is also an antagonist at 5-HT3 receptors. These 5-HT receptors are believed to play a key role in controlling gastrointestinal motility and sensitivity. The unique, dual pharmacological profile of renzapride differentiates it from other drugs currently in development for the treatment of IBS. Renzapride was discovered by Beecham Research Laboratories and investigated by them initially as a gastrointestinal prokinetic agent for the treatment of gastroesophageal reflux disease. Following a collaborative agreement, Alizyme obtained full ownership of patents relating to renzapride from SmithKline Beecham prior to its merger with GlaxoWellcome. The identification of compounds for successful research, their progress through development and the obtaining of regulatory approvals or authorisations before marketing, manufacture and/or distribution of products is not certain or a formality. This information is provided by RNS The company news service from the London Stock Exchange END RAPBLMFTMMBMBRI
1 Year Azimut Hldg Chart |
1 Month Azimut Hldg Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions